Atossa Therapeutics expands into rare diseases, advancing its investigational therapy (Z)-endoxifen as part of a broader R&D strategy, building on its biomarker

BWB News TV • 2026-08-03 13:56 UTC • By Billy Odell Tucker-Robinson

Atossa Therapeutics expands into rare diseases, advancing its investigational therapy (Z)-endoxifen as part of a broader R&D strategy, building on its biomarker-driven breast cancer program and recent rare cancer research efforts.

Share this article

𝕏 X / Twitter Facebook LinkedIn WhatsApp

📚 More from Billy’s World

📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly